Researchers Develop HARSWHEP Protein to Reduce Lung Inflammation

Recent advancements in lung disease therapies highlight significant breakthroughs in treatment approaches. Researchers from the University of Pennsylvania have developed an injectable mRNA therapy capable of delivering mRNA directly to the lower lungs, potentially transforming the management of chronic lung diseases. This innovative method uses specialized lipid nanoparticles to target areas that traditional treatments have struggled to reach. Meanwhile, a separate team at Scripps Research and aTyr Pharma has identified a novel protein, HARSWHEP, which shows promise in reducing inflammation and scarring in pulmonary sarcoidosis, a condition that has seen no new treatments in decades. Initial clinical trials of efzofitimod, based on HARSWHEP, indicate potential benefits in slowing disease progression. These studies signify a shift towards more effective therapies for chronic lung conditions that previously lacked treatment options.